Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

EpiMetaPDO

Financiado

Dissecting mechanisms of epigenetic reprogramming driving metastatic transition...

Dissecting mechanisms of epigenetic reprogramming driving metastatic transition using cancer patient-derived organoids Cancer development is a convoluted biological process that reshapes cellular identity. Genetic mutations are crucial in driving such process, yet fail to fully explain metastatic transition—a critical step in cancer evolution. For... ver más

31/05/2027

173K€

Presupuesto del proyecto: 173K€

Líder del proyecto

IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-17

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

172.75K€ | Lider

Proyectos interesantes

SAF2015-64521-R ANATOMIA FUNCIONAL DE LA ARQUITECTURA EPIGENOMICA DEL CANCER Cerrado

SAF2014-56059-R ANALISIS DE LA REPROGRAMACION METABOLICA METASTASICA EN LA B... 266K€ Cerrado

RTI2018-094049-B-I00 DISRUPCION EPIGENETICA Y GENETICA DE LAS MODIFICACIONES DEL... Cerrado

SAF2016-77241-R MODULACION EPIGENETICA DE LAS CELULAS TUMORALES PARA SU SENS... 182K€ Cerrado

BFU2017-85420-R EPIGENETICA DEL PROCESO DE TRANSICION DE EPITELIO A MESENQUI... 242K€ Cerrado

SAF2008-00923 PAPEL DE LAS SIRTUINAS EN LA REGULACION FUNCIONAL DE LA CROM... 145K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 37 meses Fecha Inicio: 2024-04-17
Fecha Fin: 2027-05-31

Presupuesto del proyecto 173K€

Descripción del proyecto Cancer development is a convoluted biological process that reshapes cellular identity. Genetic mutations are crucial in driving such process, yet fail to fully explain metastatic transition—a critical step in cancer evolution. For this reason, reprogramming driven by non-mutational epigenetic changes is increasingly recognized as a potential mechanism by which cancer cells acquire metastatic properties. Despite the genetic heterogeneity, specific transcriptional programs are activated to promote the acquisition of such properties. Therefore, understanding the role of changes at the chromatin level in facilitating metastatic transitions becomes crucial. To address this, I will use patient-derived organoids (PDOs) generated from primary colon cancer and various metastatic sites. PDOs are an optimal model system available in the hosting laboratory, providing a platform for investigation and subsequent functional validation. The project’s first goal is to profile changes in histone modifications and in the enhancer interactome, in primary and metastasis PDOs. This will identify chromatin states transitions and cis-regulatory elements with a key relevance in metastatic progression and maintenance (Aim 1). Transcription factors (TFs) with potential regulatory roles in these processes will be identified by integrating chromatin accessibility data and performing footprinting analysis (Aim 2). Functional validation of candidate TFs will be conducted using CRISPR perturbations, combined with single-cell multi-omic readout and in-vitro assays to assess PDOs' fitness and invasiveness potential (Aim 3). Altogether, in this project we will employ a comprehensive approach to investigate the molecular mechanisms underlying the activation of pro-metastatic gene regulatory networks, providing insights into the epigenetic drivers of metastatic transitions.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores